In 2025, Moderna spent $3.1 billion on R&D, a 31% decrease from the $4.5 billion budget (PDF) in 2024 and a further drop from ...

Reports fourth quarter revenue of $0.7 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.11)Reports ...

In early February 2026, the U.S. District Court for the District of Delaware denied Moderna’s bid for summary judgment in a ...

Moderna Inc (NASDAQ:MRNA) has delivered a 37% gain year-to-date, dramatically outpacing the biotech sector’s 0.4% YTD return.

Moderna (NASDAQ: MRNA) reported fourth-quarter results Friday morning that beat Wall Street’s muted expectations, delivering revenue of $678 million against estimates of $663 million and a loss of $2.

Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected revenue range to $1.6 - $2.0 billion Improves 2025 expected GAAP operating ...

Improves 2025 expected GAAP operating expenses by $0.7 billion to a range of $5.2 – $5.4 billion Increases 2025 expected year-end cash balance by $0.5 billion – $1 billion to a range of $6.5 – $7.0 ...

Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Improves 2025 expected GAAP operating expenses by $0.7 billion to a range of $5.2 - $5.4 billion ...